Cabaletta Bio (CABA) vs Relmada Therapeutics (RLMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Relmada Therapeutics (RLMD) has outperformed Cabaletta Bio (CABA) over the past year, gaining 63.3% versus a loss of 15.1%. Over five years, CABA leads with a -83.9% price change compared with -86.2% for RLMD. Relmada Therapeutics is the larger company by market cap ($333.3 million vs $328.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CABA | RLMD |
|---|---|---|
| Share price | $1.94 | $3.13 |
| Market cap | $328.07M | $333.34M |
| 1-day change | -1.78% | -3.85% |
| YTD return | -10.05% | -32.71% |
| 1-year return | -15.09% | +63.32% |
| 5-year return | -83.93% | -86.25% |
| EPS (TTM) | $-1.51 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.23 | $8.00 |
| 52-week low | $1.83 | $1.80 |
| Distance from 52-week high | -54.26% | -60.94% |
| Analyst consensus | none | none |
| Avg. price target upside | +584.75% | +244.00% |
| Average volume | 4.67M | 1.33M |
| Shares outstanding | 169.55M | 106.67M |
| Employees | 154 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLMD has outperformed CABA by 78.4 percentage points over the past year.
About Cabaletta Bio
CABA stock →Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 154 employees
About Relmada Therapeutics
RLMD stock →Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
CABA vs RLMD FAQ
Which is bigger, Cabaletta Bio or Relmada Therapeutics?
Relmada Therapeutics (RLMD) is larger, with a market capitalization of $333.34M compared with $328.07M for Cabaletta Bio (CABA).
Which stock has performed better over the past year, CABA or RLMD?
RLMD returned +63.32% over the past 12 months, compared with -15.09% for CABA (price return, excluding dividends). Past performance does not predict future results.
Are Cabaletta Bio and Relmada Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Cabaletta Bio and Biotechnology: Pharmaceutical Preparations for Relmada Therapeutics.